Influenza and Respiratory Vaccine Conference 2017 logo

Find ways to improve development of universal influenza, RSV, MERS and Pneumococcal vaccines

ABOUT THE
INFLUENZA AND RESPIRATORY VACCINE CONFERENCE

 

This event will tackle the latest issues affecting vaccines for respiratory diseases including influenza, TB, RSV and MERS to stimulate the industry to develop more effective vaccines. 

Ensure you use this event to make people aware of your expertise around key topics such as universal and seasonal flu, maternal immunization and pandemic preparedness.

SCROLL DOWN FOR THE 2017 AGENDA

 

 

2017 AGENDA

Influenza and Respiratory, Tuesday 11 April 2017

Dr Steve Projan
Influenza and Respiratory
09:10

Progress reports: Clinical updates on a next generation RSV mAb and an RSV Vaccine for older adults

  • Update the progress of MEDI8897 as it enters Ph IIb studies in infants and 2) Discuss the
  • Ph IIb data of MEDI7510 an RSV vaccine for a older adults
Dr Jerald Sadoff
Influenza and Respiratory
09:40

An adenovirus vector based vaccine, expressing F antigen: Protecting young infants against RSV, by eliciting high titer, potent neutralising antibodies and T-cell immunity

  • Recombinant human adenoviral Ad26 and Ad35 vectors encoding the RSV F gene have the potential to provide broad and durable protection against RSV in human
  • Evaluating the safety, tolerability and immunogenicity
10:40

Networking coffee break

Ms Sylvia Van Drunen Littel-van Den Hurk
Influenza and Respiratory
11:40

RSV F protein formulated with a polymer-based adjuvant platform elicits mucosal IgA production and long-lasting protective immunity

  • Mucosal administration of adjuvanted F protein
  • Induction of long-lasting immune protection
  • Stimulation of mucosal IgA, local B-cell memory development, germinal centre reactions and activation-induced cytidine deaminase
Dr Kees Leenhouts
Influenza and Respiratory
12:10

Update on the Ph I intranasal RSV vaccine SynGEM

  • Preclinical studies have shown the unique features of the SynGEM RSV F prefusion-like antigen.
  • Update on the progress of a Ph I trial to assess the safety and immunogenicity of the SynGEM intranasal spray RSV vaccine.
  • Future objectives for the use of SynGEM in different target groups
Dr Joanne Wildenbeest
Influenza and Respiratory
12:40

Landscape analysis of RSV vaccine development and how the scientific community view the resent success and failures

Dr Pamuk Bilsel
Influenza and Respiratory
12:55

Results of a PhIa study of M2SR influenza vaccine in healthy adults

  • The promise of prevention: A novel universal vaccine virus based on deletion of a portion of the M2 gene
  • Protection from drifted or mismatched flu strains
  • Breadth of protection in multiple age groups
13:10

Networking Lunch & Poster Session

Influenza and Respiratory
14:40

The gold standard for human challenge studies in respiratory vaccines

  • The gold standard for human challenge studies in respiratory vaccines
  • Results of studies of antiviral or vaccine approaches in the human challenge model have been predictive of efficacy in the real world
  • What we’ve learnt: Sharing knowledge over 7 clinical studies involving more than 750+ volunteers for RSV
  • Senior representative, hVIVO
Dr Peter Palese
Influenza and Respiratory
15:10

Fc-FcγR interactions of anti-influenza stalk mAbs: Mechanistic data to support universal flu vaccine development

  • Studying Fc receptor interactions: How are Abs working to give immunity?
  • Gaining optimal activation of Fc-mediated effector functions by influenza virus hemagglutinin antibodies
  • Potential applications to other viruses  
Dr Ted Ross
Influenza and Respiratory
15:40

Developing new vaccine for H1N1 and H3N2 influenza A viruses

  • Advanced development of more effective universal influenza vaccines
  • Using Computationally Optimized Broadly Reactive Antigen (COBRA) - a major step in the right direction towards a universal vaccine
16:10

Networking coffee break

Professor Florian Krammer
Influenza and Respiratory
16:40

Influenza virus neuraminidase as target for broadly protective vaccines

Ms Nathalie Landry
Influenza and Respiratory
17:10

Immunogenicity of a plant-derived quadrivalent VLP vaccine in adults and the elderly

  • Phase 2 clinical results on QIV seasonal VLPs in healthy adults and elderly
  • Comparison of humoral and cell-mediated immune responses induced by VLPs
Influenza and Respiratory
17:40

Virospot MN Assay methodology and research findings

Senior representative, Viroclinics
Professor David Weiner
Influenza and Respiratory
18:10

Facilitated DMAb in vivo delivery for rapid protection from difficult immune targets

  • Major improvements in DNA vaccine technology over the past decade has reinvigorated this platform which has conceptual advantages over traditional vaccine platforms and for invivo antigen delivery
  • In humans prior generations of DNA vaccines were poorly immunogenic. Through multiple improvements including synthetic optimization, formulation technology and enhanced EP delivery this technology exhibits improved performance in vivo driving immune responses similar or superior to live viral vectors
  • We have refocused this approach for direct DNA (DMAb) delivery of Monoclonal antibodies targeting EID produced invivo and compare this approach to vaccination for rapid immune protection against important pathogens  
18:40

Chair’s closing remarks and close of congress day 2

18:45

Networking Drinks & Party

last published: 23/Jan/17 15:06

 

Influenza and Respiratory, Wednesday 12 April 2017

Dr Rino Rappuoli
Influenza and Respiratory
09:10

Scientific challenges and results on developing a new pertussis vaccine

  • The need for a new pertussis vaccine with longer lasting immunity
  • Challenges in making an effective pertussis vaccines: Cyclical by nature, waning immunity, asymptomatic carriers
Giovanni Della Cioppa
Influenza and Respiratory
09:40

Disease modifying vaccines in Chronic Obstructive Pulmonary Disease (COPD)

-          Presenting early stage development of a vaccine to prevent the bacterial infections that exacerbate COPD
-          COPD is a very common, chronic, progressive, respiratory illness of adults, which can be triggered by bacterial infections
-          A vaccine to prevent these respiratory infections could modify the clinical progression of COPD, and improve quality of life
Influenza and Respiratory
10:10

How much cross protection between serotypes is enough for a pneumococcal vaccine?

  • Are the current serotypes in the vaccine enough protection?
  • How can we measure and predict this?
  • Comparing cross protection with other vaccine candidates
10:40

Networking coffee break

Mr Scot Roberts
Influenza and Respiratory
11:30

NasoShieldTM anthrax vaccine candidate provides protection from challenge and rapid immunogenicity following a single intranasal dose

 
  • Serotype coverage and conjugate vaccines
  • Carriage, efficacy and effectiveness data
  • With no immune correlate of protection for pneumococcal proteins, what basis do you move into the clinic?
  • What would constitute an adequate proof of concept study?
Dr Danilo Casimiro
Influenza and Respiratory
12:00

Tuberculosis vaccine R&D: Addressing a global epidemic

 
  • New insights into why immunity from BCG vaccine is so variable
  • Paving the way we develop new TB vaccines
  • Identify immune correlates that could facilitate TB vaccine development
12:30

Networking Lunch & Poster Session

Dr Alan R. Hinman
13:40

The eradication of Polio: Have we succeeded?


-    Measuring and monitoring the success of eradication
-    End game and strategic plan
-    What’s next? Can we eradicate measles?
 
Professor Robert Daum
14:10

A call for greater consideration for the role of vaccines in national strategies to combat antibiotic-resistant bacteria


-    Recommendations from the National Vaccine Advisory Committee
-    Use of vaccines to prevent the infections that could or have developed AMR to antibiotics, in adjunction to antibiotic stewardship
-    Examples in Haemophilus influenza, Streptococcus, Staphylococcus aureus

 
Dr Danilo Casimiro
14:40

Panel: How much efficacy is enough? What are the implications of a vaccine no longer being a replacement technology but a companion technology?


-    The concept of partially protected vaccines like malaria, TB, NTDs where the clinical efficacy is no longer 85/90% but closer to 40% 
-    Future of vaccine development 
-    The combining drivers of technology and emerging diseases

More panelists to be announced shortly
15:30

Chair’s closing remarks and close of congress

last published: 23/Jan/17 15:07

 

Sign up for event updates

 

WHO ATTENDS?

  • Pharma
  • Biotech
  • National and International Government
  • Non-Profit Organizations
  • Academics And Research Institutions​

JOB TITLES

  • CEO / CSO / COO
  • CMO / Head of Scientific Affairs
  • Head of Influenza
  • Head of Infectious Disease
  • Head of R&D
  • Head of Regulatory Affairs
  • Head of Manufacturing
  • Head of Immunology

 

 

WHO SPONSORS?

This is a key opportunity for specialists in influenza and respiratory vaccines from:

  • Platform Technology Providers
  • Biotechs
  • Big Pharma
  • Logistics / Cold Chain ​